Network origin in Alan Beggs first degree
Entity | Entity type | Industry | |
---|---|---|---|
Subsidiary | Biotechnology | 6 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Alan Beggs via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Investment Managers | Private Equity Investor | |
Precede Biosciences, Inc.
Precede Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Precede Biosciences is a company that aims to improve success rates in drug development and clinical practice by breaking down the barriers to precision medicine. The company is based in Boston, MA. The company seeks to redefine what can be learned from a simple blood draw to better target medicines to the right patients. Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. The CEO of the company is Rehan Verjee. | Miscellaneous Commercial Services | Director/Board Member | |
5am Partners Vi LLC | Corporate Officer/Principal | ||
SYNGENE INTERNATIONAL LIMITED | Miscellaneous Commercial Services | Director/Board Member | |
RALLYBIO CORPORATION | Biotechnology | Director/Board Member | |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
Grace Science Foundation
Grace Science Foundation Miscellaneous Commercial ServicesCommercial Services Grace Science Foundation is a biotechnology company that was founded in 2017 by Matt Wilsey and Dr. Carolyn Bertozzi. The private company is based in San Francisco, CA. The company focuses on developing novel therapies based on the function of NGLY1, a key enzyme involved in proteostasis. Grace Science Foundation's deep knowledge of the NGLY1 pathway enables them to identify new ways of treating NGLY1 deficiency as well as more common diseases. | Miscellaneous Commercial Services | Consultant / Advisor | |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Miscellaneous Commercial Services | Founder | |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Biotechnology | Chief Tech/Sci/R&D Officer | |
5AM Partners V LLC | Corporate Officer/Principal | ||
Università degli Studi di Roma Tor Vergata | College/University | Undergraduate Degree | |
MOLMED S.P.A. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Università degli Studi di Modena e Reggio Emilia | College/University | Corporate Officer/Principal | |
San Raffaele-Telethon Institute for Gene Therapy | Director/Board Member | ||
European Molecular Biology Organization | Corporate Officer/Principal | ||
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Miscellaneous Commercial Services | Director/Board Member | |
ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Biotechnology | Chief Tech/Sci/R&D Officer | |
5AM Opportunities I GP LLC | Corporate Officer/Principal | ||
Immuneel Therapeutics Pvt Ltd.
Immuneel Therapeutics Pvt Ltd. Hospital/Nursing ManagementHealth Services Immuneel Therapeutics Pvt Ltd. operates as a cancer treatment center. The company was founded by Kiran Mazumdar-Shaw, Kush M. Parmar and Siddhartha Mukherjee is headquartered in Bengaluru, India. | Hospital/Nursing Management | Founder | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree | |
Princeton University | College/University | Undergraduate Degree | |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
Harvard Medical School | College/University | Doctorate Degree | |
Cruz Blanca Initiative, Inc. | Founder | ||
SCPHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
501 ACQU | Financial Conglomerates | Chief Executive Officer | |
PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member | |
AKOUOS | Biotechnology | Director/Board Member | |
Rallybio LLC
Rallybio LLC Miscellaneous Commercial ServicesCommercial Services Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT. | Miscellaneous Commercial Services | Director/Board Member | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
ENTRADA THERAPEUTICS, INC. | Biotechnology | Chairman | |
VOR BIOPHARMA INC. | Biotechnology | Chief Executive Officer | |
Rallybio Holdings LLC
Rallybio Holdings LLC Medical/Nursing ServicesHealth Services Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT. | Medical/Nursing Services | Director/Board Member | |
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
United States | 31 |
Italy | 5 |
India | 3 |
France | 3 |
Switzerland | 2 |
Sectoral
Health Technology | 20 |
Commercial Services | 7 |
Consumer Services | 6 |
Finance | 4 |
Health Services | 3 |
Operational
Director/Board Member | 21 |
Corporate Officer/Principal | 11 |
Independent Dir/Board Member | 9 |
Chief Tech/Sci/R&D Officer | 5 |
Doctorate Degree | 4 |
Most connected contacts
Insiders | |
---|---|
Kush Parmar | 32 |
Fulvio Mavilio | 10 |
Cassie Hogenkamp | 2 |
Jason Schwartz | 1 |
David Smethurst | 1 |
Morten Sogaard | 1 |
- Stock Market
- Insiders
- Alan Beggs
- Company connections